eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
Get Medicines Compendium UK app here

Molnlycke Health Care

Two Omega Drive, Irlam, Manchester, M44 5BJ , UK
Telephone: +44 (0)161 777 2600
Fax: +44 (0)161 777 2601
WWW: http://www.molnlycke.com
Medical Information Direct Line: +44 (0)161 777 2628
Medical Information e-mail: ukmedical.information@molnlycke.com
Customer Care direct line: +44 (0)161 777 2600
Medical Information Fax: +44 (0)161 621 2045

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?


Summary of Product Characteristics last updated on the eMC: 01/02/2008
SPC Icthaband


Go to top of the page
1. NAME OF THE MEDICINAL PRODUCT

Icthaband.


Go to top of the page
2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Zinc Oxide BP 15% w/w; Ichthammol BP 2% w/w.


Go to top of the page
3. PHARMACEUTICAL FORM

Open wove bleached cotton bandage impregnated with the paste formulation.


Go to top of the page
4. CLINICAL PARTICULARS

Go to top of the page
4.1 Therapeutic indications

Icthaband may be used for the following conditions: subacute eczematous conditions; chronic eczema, where tar is not tolerated; subacute gravitational eczema and all other forms of leg eczema; varicose and gravitational ulcers, in conjunction with a compression bandage, when a protective barrier to thin and fragile skin is required.


Go to top of the page
4.2 Posology and method of administration

For topical use. Adults, the elderly, and children: Frequency of dressing changes is at the discretion of the responsible physician. There are no differences in use between adults, children and the elderly.


Go to top of the page
4.3 Contraindications

Hypersensitivity to any ingredient of the paste, and acute eczematous lesions.


Go to top of the page
4.4 Special warnings and precautions for use

Avoid use on grossly macerated skin. The skin of leg ulcers is easily sensitised to topical medicaments including preservatives. Sensitisation should be suspected in patients particularly where there is deterioration of the ulcer or surrounding skin. Such patients should be referred for special diagnosis including patch testing. One of the functions of occlusive bandages is to increase absorption. Care should be taken, therefore, if it is decided to apply topical steroid preparations under these bandages as their absorption may be significantly increased.


Go to top of the page
4.5 Interaction with other medicinal products and other forms of interaction

None stated.


Go to top of the page
4.6 Pregnancy and lactation

No special precautions required.


Go to top of the page
4.7 Effects on ability to drive and use machines

Not applicable.


Go to top of the page
4.8 Undesirable effects

Not applicable.


Go to top of the page
4.9 Overdose

Not applicable.


Go to top of the page
5. PHARMACOLOGICAL PROPERTIES

Go to top of the page
5.1 Pharmacodynamic properties

The product is a paste bandage with the active constituent presented in a glycerine, modified starch and castor oil based paste spread onto a cotton bandage. Zinc Oxide as a zinc salt has astringent properties and has been shown to play a role in wound healing. Ichthammol has an antipruritic action and has slight bacteriostatic properties. These substances are well established in use, but only the subject of brief references in recent literature and pharmacopoeias (e.g. Martindale). Much of the therapeutic action of paste bandages is attributable to the bandaging technique, the physical support and protection provided and to the maintenance of moist wound healing conditions.


Go to top of the page
5.2 Pharmacokinetic properties

The pharmacokinetics of the active ingredient are those relevant to topical application of the substances through whole or broken skin. Contemporary literature describes the biochemical properties but with the exception of the zinc salts does directly relate these properties to the disease states being treated. Zinc compounds are the subject of current re-appraisal for their role in wound healing.


Go to top of the page
5.3 Preclinical safety data

None stated.


Go to top of the page
6. PHARMACEUTICAL PARTICULARS

Go to top of the page
6.1 List of excipients

Glycerol

Castor oil

Tapioca starch

Citric acid

Propylhydroxybenzoate

Water purified

Open weaved cotton bandage


Go to top of the page
6.2 Incompatibilities

None stated.


Go to top of the page
6.3 Shelf life

Thirty months.


Go to top of the page
6.4 Special precautions for storage

Store in a dry place not exceeding 25oC.


Go to top of the page
6.5 Nature and contents of container

Bandages are wrapped individually in waxed paper or polythene film and then placed in a nylon/foil/polythene laminate bag in a cardboard carton, or a sealed polythene bag in a cardboard carton. 12 cartons are packed per corrugated cardboard outer.


Go to top of the page
6.6 Special precautions for disposal and other handling

None.


Go to top of the page
7. MARKETING AUTHORISATION HOLDER

Medlock Medical Ltd., Tubiton House, Oldham, OL1 3HS.


Go to top of the page
8. MARKETING AUTHORISATION NUMBER(S)

PL 21248/0018


Go to top of the page
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

29th June 2007.


Go to top of the page
10. DATE OF REVISION OF THE TEXT

29th June 2007.



More information about this product

Link to this document from your website: http://www.medicines.org.uk/emc/medicine/4540/SPC/


Active Ingredients/Generics

 
   zinc oxide
   ichthammol